𝔖 Bobbio Scriptorium

✦ LIBER ✦

Statins in patients with CKD prove beneficial in reducing cardiovascular events and mortality but show no benefit in patients on dialysis

✍ Scribed by Krishnan, S.; Jacobson, T. A.

Book ID: 121795935
Publisher: BMJ Publishing Group
Year: 2012
Tongue: English
Weight: 46 KB
Volume: 18
Category: Article
ISSN: 1356-5524
DOI: 10.1136/eb-2012-101059

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Review: Statins reduce mortality and maj

Review: Statins reduce mortality and major vascular events in patients with no history of CV disease

✍ Elley, C. Raina 📂 Article 📅 2013 🏛 American College of Physicians 🌐 English ⚖ 276 KB

Beneficial Impact of Xuezhikang on Cardi

Beneficial Impact of Xuezhikang on Cardiovascular Events and Mortality in Elderly Hypertensive Patients With Previous Myocardial Infarction From the China Coronary Secondary Prevention Study (CCSPS)

✍ Li, Jian-Jun; Lu, Zong-Liang; Kou, Wen-Rong; Chen, Zuo; Wu, Yang-Feng; Yu, Xue-H 📂 Article 📅 2009 🏛 Sage Publications 🌐 English ⚖ 268 KB

Benefits of pravastatin on cardiovascula

Benefits of pravastatin on cardiovascular events and mortality in older patients with coronary heart disease are equal to or exceed those seen in younger patients: results from the LIPID trial

✍ D Hunt; P Young; J Simes 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 39 KB

In navigator, the angiotensin receptor b

In navigator, the angiotensin receptor blocker valsartin modestly reduced the progression to type 2 diabetes but had no effect on cardiovascular events in higher-risk patients with impaired glucose tolerance

✍ Michael J. Bloch; Jan N. Basile 📂 Article 📅 2010 🏛 Le Jacq Communications, Inc. 🌐 English ⚖ 246 KB

Dietary supplementation with n -3 polyun

Dietary supplementation with n -3 polyunsaturated fatty acids, but not vitamin E, reduced the risk of mortality and morbidity after recent MI: Vitamin E had no effect on the risk of cardiovascular death, MI and stroke in patients at high risk for cardiovascular events but without LV dysfunction or HF

✍ Julie E. Buring 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 250 KB

Trial finds candesartan reduces cardiova

Trial finds candesartan reduces cardiovascular deaths and hospital admissions in people with heart failure, but may not affect all cause mortality: Abstracted from: Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003; 362(9386): 759–66

📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 134 KB